| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
T-3764518 targets stearoyl-CoA desaturase (SCD), a rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids. SCD is a key metabolic enzyme involved in lipid metabolism and is considered a therapeutic target for metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease.
|
|---|---|
| ln Vitro |
In vitro, T-3764518 demonstrates high potency against SCD with an IC₅0 of 4.7 nM. The compound is supplied as a high-purity solid suitable for biochemical and cellular studies. It has a molecular formula of C20H1₇F₆N₅O2 and molecular weight 473.37.
|
| ln Vivo |
In vivo data for T-3764518 are limited. As a potent SCD inhibitor, the compound is expected to reduce monounsaturated fatty acid levels and modulate lipid metabolism in preclinical models. Further in vivo efficacy studies are needed to characterize its therapeutic potential.
|
| Enzyme Assay |
For in vitro enzyme binding assays, T-3764518 is evaluated using recombinant SCD enzyme in microsomal or cell-based activity assays. The compound is incubated with the enzyme and a radiolabeled or fluorescent substrate (e.g., stearoyl-CoA), and the conversion to oleoyl-CoA is measured to determine inhibitory activity. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cellular assays, T-3764518 is dissolved in DMSO and applied to hepatocytes or adipocytes to assess its effects on lipid metabolism. Cellular lipid content, fatty acid composition, and SCD activity are measured using gas chromatography, mass spectrometry, or biochemical assays. The compound is typically tested at concentrations around its IC₅0.
|
| Animal Protocol |
In vivo animal studies with T-3764518 typically involve oral administration in rodent models of metabolic disease (e.g., diet-induced obesity or diabetes models). Endpoints include body weight, food intake, plasma lipid profiles, glucose tolerance, and liver fat content.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for T-3764518 are limited. The compound has high purity (99.9%) and is available as a solid powder. It is intended for in vitro and preclinical research applications. Detailed PK parameters are not publicly available.
|
| Toxicity/Toxicokinetics |
Toxicology data for T-3764518 are limited. As a metabolic enzyme inhibitor, the compound may affect normal lipid metabolism; therefore, careful dose optimization is required. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
T-3764518 (CAS#: 1809151-56-1) has the molecular formula C20H1₇F₆N₅O2 and molecular weight 473.37. The chemical name is (5-(6-(4-(trifluoromethyl)-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)pyridazin-3-yl)-1,3,4-oxadiazol-2-yl)methanol. It is a research reagent only.
|
| Molecular Formula |
C20H17F6N5O2
|
|---|---|
| Molecular Weight |
473.371704816818
|
| Exact Mass |
473.128
|
| CAS # |
1809151-56-1
|
| PubChem CID |
124192339
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
650
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1(C2C=CC(C(F)(F)F)=CC=2)CCN(C2=CC=C(C3=NN=C(CO)O3)N=N2)CC1)(F)F
|
| InChi Key |
TVGUBMHUHTULAD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17F6N5O2/c21-19(22,23)13-3-1-12(2-4-13)18(20(24,25)26)7-9-31(10-8-18)15-6-5-14(27-28-15)17-30-29-16(11-32)33-17/h1-6,32H,7-11H2
|
| Chemical Name |
[5-[6-[4-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyridazin-3-yl]-1,3,4-oxadiazol-2-yl]methanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~95 mg/mL (~200.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.17 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 31.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3.17 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 31.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 3 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1125 mL | 10.5626 mL | 21.1251 mL | |
| 5 mM | 0.4225 mL | 2.1125 mL | 4.2250 mL | |
| 10 mM | 0.2113 mL | 1.0563 mL | 2.1125 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
